Clinical Trial

Study on Deep Transcranial Magnetic Stimulation for Enhancing Insight

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Impaired insight is a key factor in the conversion of high-risk individuals to schizophrenia, but there is a lack of targeted interventions. We found that an electroencephalogram (EEG) signal, error-related negativity (ERN), was closely related to impaired insight. The more pronounced the ERN attenuation in patients with high-risk and first-episode psychosis, the more severe the impairement of clinical insight. ERN is a negative potential that appears at the frontal and central scalp electrode locations within 100 ms after an erroneous behavioral response, reflecting the activity of the brain's error-monitoring system. Research has shown that the brain region underlying ERN is partly located in the anterior cingulate cortex (ACC). Other research has reported that the activity extending from the ACC to the medial prefrontal cortex (mPFC) is associated with impaired insight in patients with various disorders. Therefore, this project targets mPFC/ACC and uses deep transcranial magnetic stimulation (dTMS) for targeted modulation, with an exploratory observation of changes in patients' insight before and after neurostimulation.
Trial Details
NCT Number NCT06831877
Lead Sponsor Shanghai Mental Health Center
Conditions Impaired Insight
Enrollment 138 participants
Start Date 2023-12-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-18